Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607997 · ClinicalTrials.gov registry record · Phase 2
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
A Phase 2 study of Acute Myeloid Leukemia and Leukemia, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT00607997: Completed Phase 2 study of Acute Myeloid Leukemia and Leukemia, sponsored by Sunesis Pharmaceuticals.
NCT00607997 is a Phase 2 study of Acute Myeloid Leukemia and Leukemia that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 113 participants, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00607997, a Phase 2 study of Acute Myeloid Leukemia and Leukemia, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
Primary Outcome
Combined remission rate (complete remission \[CR\] + complete remission with incomplete platelet recovery \[CRp\]) of vosaroxin of patients ≥ 60 years old with previously untreated (de novo or secondary) AML are presented by treatment group for all treated analysis set. Per IWG criteria, a CR requires bone marrow blasts \< 5%, absolute neutrophil count (ANC) \> 1000 cells/uL, and platelet (plt) count \> 100,000 plt/uL. The criteria for CRp are the same as those for CR, except for platelet count
Conditions Studied
Interventions
- DRUG vosaroxin
Study Locations (20)
Arizona
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic Scottsdale - Scottsdale
Illinois
- Rush University Medical Center - Chicago
- The University of Chicago - Chicago
Indiana
- Indiana University Cancer Center - Indianapolis
- St. Francis Hospital & Health Systems at Beech Grove Campus - Indianapolis
Kansas
- Cancer Center of Kansas - Wichita
- Cancer Center of Kansas - Wichita
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- Scripps Cancer Center - La Jolla
Colorado
- Rocky Mountain Blood and Marrow Transplant Program - Denver
Louisiana
- LSU Health Sciences Center at Shreveport - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2008-05-15 |
| Est. Completion | 2009-11-23 |
| Phase | Phase 2 |
What the finished NCT00607997 record still lists
NCT00607997 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target.
The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which vosaroxin is the first listed.
NCT00607997 names 20 study sites across 15 states, led by Arizona, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT00607997 about?
NCT00607997 is a clinical study titled "Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia". This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
What is the current status of trial NCT00607997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2008-05-15. Estimated completion is 2009-11-23.
What conditions does trial NCT00607997 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Acute Disease, Nonlymphocytic Leukemia.
What interventions are being tested in trial NCT00607997?
The interventions under investigation include: vosaroxin (DRUG).
Who is sponsoring clinical trial NCT00607997?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00607997 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00607997's enrollment target sits among peer trials
113 72nd of 306 higher than 235 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI